These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 31180577

  • 1. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
    Gángó A, Alpár D, Galik B, Marosvári D, Kiss R, Fésüs V, Aczél D, Eyüpoglu E, Nagy N, Nagy Á, Krizsán S, Reiniger L, Farkas P, Kozma A, Ádám E, Tasnády S, Réti M, Matolcsy A, Gyenesei A, Mátrai Z, Bödör C.
    Int J Cancer; 2020 Jan 01; 146(1):85-93. PubMed ID: 31180577
    [Abstract] [Full Text] [Related]

  • 2. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA.
    JAMA Oncol; 2015 Apr 01; 1(1):80-7. PubMed ID: 26182309
    [Abstract] [Full Text] [Related]

  • 3. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ.
    Cancer; 2019 Feb 15; 125(4):559-574. PubMed ID: 30508305
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
    Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, Dilhuydy MS, Nollet D, Guieze R, Feugier P, Roos-Weil D, Willems L, Michallet AS, Delmer A, Hormigos K, Levy V, Cymbalista F, Baran-Marszak F, French Innovative Leukemia Organization (FILO) CLL Group.
    Blood; 2019 Aug 15; 134(7):641-644. PubMed ID: 31243043
    [Abstract] [Full Text] [Related]

  • 5. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
    Woyach JA, Jones D, Jurczak W, Robak T, Illés Á, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V.
    Blood; 2024 Sep 05; 144(10):1061-1068. PubMed ID: 38754046
    [Abstract] [Full Text] [Related]

  • 6. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
    Lampson BL, Brown JR.
    Expert Rev Hematol; 2018 Mar 05; 11(3):185-194. PubMed ID: 29381098
    [Abstract] [Full Text] [Related]

  • 7. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Sharma S, Galanina N, Guo A, Lee J, Kadri S, Van Slambrouck C, Long B, Wang W, Ming M, Furtado LV, Segal JP, Stock W, Venkataraman G, Tang WJ, Lu P, Wang YL.
    Oncotarget; 2016 Oct 18; 7(42):68833-68841. PubMed ID: 27626698
    [Abstract] [Full Text] [Related]

  • 8. Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Bödör C, Kotmayer L, László T, Takács F, Barna G, Kiss R, Sebestyén E, Nagy T, Hegyi LL, Mikala G, Fekete S, Farkas P, Balogh A, Masszi T, Demeter J, Weisinger J, Alizadeh H, Kajtár B, Kohl Z, Szász R, Gergely L, Gurbity Pálfi T, Sulák A, Kollár B, Egyed M, Plander M, Rejtő L, Szerafin L, Ilonczai P, Tamáska P, Pettendi P, Lévai D, Schneider T, Sebestyén A, Csermely P, Matolcsy A, Mátrai Z, Alpár D.
    Br J Haematol; 2021 Jul 18; 194(2):355-364. PubMed ID: 34019713
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
    Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A.
    Blood; 2017 Mar 16; 129(11):1469-1479. PubMed ID: 28049639
    [Abstract] [Full Text] [Related]

  • 11. Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
    Pozzo F, Forestieri G, Vit F, Ianna G, Tissino E, Bittolo T, Papotti R, Gaglio A, Terzi di Bergamo L, Steffan A, Polesel J, Bulian P, Laureana R, Tafuri A, Chiarenza A, Di Raimondo F, Olivieri J, Zaja F, Laurenti L, Del Principe MI, Postorino M, Del Poeta G, Bomben R, Zucchetto A, Rossi D, Gattei V.
    Leukemia; 2024 Aug 16; 38(8):1712-1721. PubMed ID: 38914716
    [Abstract] [Full Text] [Related]

  • 12. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
    Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.
    N Engl J Med; 2014 Jun 12; 370(24):2286-94. PubMed ID: 24869598
    [Abstract] [Full Text] [Related]

  • 13. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
    Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC.
    J Clin Oncol; 2017 May 01; 35(13):1437-1443. PubMed ID: 28418267
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, Byrd JC, Johnson AJ, Lozanski G.
    Leukemia; 2017 Jul 01; 31(7):1645-1647. PubMed ID: 28366935
    [No Abstract] [Full Text] [Related]

  • 16. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
    Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ.
    Nat Commun; 2016 May 20; 7():11589. PubMed ID: 27199251
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Wiśniewski K, Puła B.
    Int J Mol Sci; 2024 May 11; 25(10):. PubMed ID: 38791284
    [Abstract] [Full Text] [Related]

  • 19. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM, Staudt LM.
    Cancer Cell; 2014 Jul 14; 26(1):11-3. PubMed ID: 25026208
    [Abstract] [Full Text] [Related]

  • 20. Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.
    Wist M, Meier L, Gutman O, Haas J, Endres S, Zhou Y, Rösler R, Wiese S, Stilgenbauer S, Hobeika E, Henis YI, Gierschik P, Walliser C.
    J Biol Chem; 2020 Apr 24; 295(17):5717-5736. PubMed ID: 32184360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.